

# Expression of AA4.1 marks lymphohematopoietic progenitors in early mouse development

Toshiyuki Yamane<sup>a,b,1</sup>, Naoki Hosen<sup>a</sup>, Hidetoshi Yamazaki<sup>b</sup>, and Irving L. Weissman<sup>a,1</sup>

<sup>a</sup>Departments of Pathology and Developmental Biology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305; and <sup>b</sup>Department of Physiology and Regenerative Medicine, Mie University Graduate School of Medicine, Tsu 514-8507, Japan

Contributed by Irving L. Weissman, April 14, 2009 (sent for review December 18, 2008)

The hematopoietic system of mice is established during the early to midgestational stage of development. However, the earliest lymphohematopoietic progenitors that appear during mouse development have been less well characterized compared with the hematopoietic stem cell compartment of fetal liver and bone marrow. We isolated the earliest lymphohematopoietic progenitors by using embryonic stem (ES) cell culture *in vitro*. Cells with the c-Kit<sup>+</sup>Lin<sup>-</sup> cell surface phenotype were present abundantly in ES cells cocultured with stromal cell lines. We further separated the cells into two distinct cell subsets based on AA4.1 expression. Although AA4.1<sup>+</sup> and AA4.1<sup>-</sup> cells had equivalent potency to generate myeloid cell lineages, the lymphoid potential in ES-cell-derived cells was largely restricted to the cells expressing AA4.1. The same cell type was present abundantly in the early yolk sac and in fewer numbers (≈5% of that in the yolk sac) in the caudal half of the developing embryos. These data suggest that AA4.1 is a cell surface marker that can identify the earliest lymphohematopoietic progenitors in mouse development.

embryonic stem cell | embryonic | hematopoiesis | yolk sac

Hematopoietic stem cells (HSCs) are a rare subset of cells that are capable of self-renewal and differentiation into all mature blood cell lineages (1). During mouse development, the first hematopoietic cells appear in yolk sac (YS) blood islands (2) and subsequently in the aorta-gonad-mesonephros (AGM) (3) and placental regions (4, 5). After the establishment of circulation, hematopoietic progenitors colonize the fetal liver (FL) and later the bone marrow (BM) and spleen (6). Although the site where HSCs initially originate in the mouse embryo is controversial (7–11), in late fetal life, the BM becomes the major site of hematopoiesis where HSCs reside, and it produces mature blood cells throughout life (12, 13). Antibody-mediated phenotyping of cell surface molecules and cell sorting techniques have been used to identify and isolate a rare HSC compartment from hematopoietic tissues, and the techniques are especially successful to isolate pure HSCs from FL and BM (13–16).

Embryonic stem (ES) cells, pluripotent cell lines derived from the inner cell mass of blastocysts (17, 18), or induced pluripotent stem cells generated from fibroblasts by the transduction of transcription factors (19) are an alternative source of hematopoietic cells. Pluripotent stem cell lines can be a theoretically unlimited source of HSCs because the cells expand indefinitely in an undifferentiated state *in vitro* (20–22). Extrapolated to humans, pluripotent stem cell lines can be a potential candidate source for treating hematopoietic disorders. ES cell differentiation *in vitro* recapitulates early embryonic development *in vivo*, thus providing a potent analytical tool of early development. The potency of ES cells to generate myeloid and lymphoid lineage cells *in vitro* has been reported (23–26). Despite these observations, ES-cell-derived hematopoietic cells *in vitro* are known to have only a limited ability to engraft adult mice and lack long-term multilineage repopulating activity *in vivo* (27), although ES cells could contribute to the hematopoietic system for at least 10 months when replanted into blastocysts giving rise to chimeric mice (28–30). The presence of lymphohematopoietic

progenitors in ES cell cultures was suggested initially by a report that examined the hematopoietic potential of cells derived from overexpressed BCR/ABL in ES cells: the ES cells acquired improved ability to engraft mice, and hematopoietic progenitors with both myeloid and lymphoid potential were demonstrated by *in vivo* assay (31). In addition, HOXB4 with or without enforced expression of Cdx4 was recently reported to confer long-term multilineage repopulating capability on ES-cell-derived progenitors (32, 33). However, whether these genes modified the transplantability of preexisting HSCs or changed the self-renewal and differentiation potential of ES-cell-derived hematopoietic progenitors into HSC-like properties is not known, because these experiments depended on exogenously introduced genes.

We examined cell surface phenotypes and differentiation potentials of ES-cell-derived hematopoietic progenitors developed on stromal cell coculture to determine the earliest lymphohematopoietic progenitors in early embryos. We found that a cell population positive for both c-Kit and AA4.1 expression appearing on the early ES cell culture had both myeloid and lymphoid lineage potentials. In embryos developing *in utero*, AA4.1<sup>+</sup> lymphohematopoietic progenitors were found mainly in the YS, and some in the caudal half (CH) of embryos. The cell population represents the earliest subset of cells with lymphohematopoietic properties during development.

## Results

### Expression of AA4.1 on ES-Cell-Derived Hematopoietic Progenitors.

To derive hematopoietic cells from undifferentiated mouse ES cells, we cocultured ES cells on stromal cell lines; ST2 (34) or macrophage colony-stimulating factor-deficient OP9 (35, 36) was used for this purpose (Fig. 1*A*). Stepwise culture on the ST2 stromal cell line was established based on the OP9 system (23). We could not find any differences in the timing of hematopoietic cell appearance, expression of cell surface molecules, and characteristics of generated hematopoietic cells (described below) between the OP9 and ST2 systems. In both culture systems, starting from singly dissociated cells, ES cells extensively divided and formed colonies consisting of differentiated cells on stromal cells (Fig. 1*B Left*). On day 5 or day 6 of differentiation, a single cell suspension was replated onto a fresh stromal cell layer. Small hematopoietic cell clusters were observable a couple of days later (Fig. 1*B Center*). These cells grew rapidly and formed large hematopoietic clusters by 2 weeks of differentiation (Fig. 1*B Right*).

We examined the time point at which hematopoietic activity appears during *in vitro* differentiation of ES cells by checking

Author contributions: T.Y., N.H., and I.L.W. designed research; T.Y. and N.H. performed research; T.Y. and H.Y. contributed new reagents/analytic tools; T.Y., N.H., H.Y., and I.L.W. analyzed data; and T.Y. and I.L.W. wrote the paper.

Conflict of interest statement: I.L.W. was formerly a member of the scientific advisory board of Amgen and owns significant Amgen stock; he cofounded and consulted for Systemix, is a cofounder and director of Stem Cells, Inc., cofounded and is a director of Cellerant, Inc. All other authors have no conflicting financial interests.


<sup>1</sup>To whom correspondence may be addressed. E-mail: yamanet@doc.medic.mie-u.ac.jp or irv@stanford.edu.

This article contains supporting information online at [www.pnas.org/cgi/content/full/0904090106/DCSupplemental](http://www.pnas.org/cgi/content/full/0904090106/DCSupplemental).









**Fig. 4.** Cell surface antigen expression of embryonic stem (ES)-cell-derived lymphohematopoietic progenitor cell subsets. (A) Cell surface marker expression in  $c\text{-Kit}^+\text{AA4.1}^+$  cell subset. (B) CD41 and AA4.1 expression in the  $c\text{-Kit}^+$  cell fraction. The numbers indicate the percentages within the parent population.

other stem-cell-related markers in  $c\text{-Kit}^+\text{AA4.1}^+$  cells. In addition to the expression of the panhematopoietic marker CD45,  $c\text{-Kit}^+\text{AA4.1}^+$  cells expressed CD34 and CD41 ( $\alpha\text{4Ib}$  integrin and GPIIb) (Fig. 4A), which were previously shown to be expressed on ES-cell-derived hematopoietic progenitors, although their lymphoid potential has not been tested (58, 59). Especially, CD41 is known to be expressed on YS and AGM hematopoietic progenitors and has been used to isolate these progenitors (58–60). We compared the expression pattern of CD41 and AA4.1 in the  $c\text{-Kit}^+$  cell fraction and found that  $\approx 80\%$  of the CD41 $^+$  cells coexpressed AA4.1, but the remaining 20% were unmarked with AA4.1 (Fig. 4B). The results indicated that CD41 expression marks wider cell populations compared with AA4.1. Thus, AA4.1 expression enables the further enrichment of lymphohematopoietic progenitors in differentiating ES

**Table 1. Quantification of  $c\text{-Kit}^+\text{AA4.1}^+$  cells in E9.5 embryos**

		Exp. 1	Exp. 2	Exp. 3
No. embryos*		8	6	7
No. somite pairs†		21.1	23.8	28.2
No. $c\text{-Kit}^+\text{AA4.1}^+\text{CD45}^+\text{Ter119}^-$ cells‡	CH	20	44	75
	YS	353	920	1,419


\*The number of embryos analyzed. Pooled littermate embryos were used in each experiment.

†The average number of somite pairs for the analyzed embryos.

‡The average number of  $c\text{-Kit}^+\text{AA4.1}^+\text{CD45}^+\text{Ter119}^-$  cells within the indicated location of an embryo estimated from the pooled analysis of caudal half (CH) and yolk sac (YS) cells.

cells. We also examined Sca-1 (Ly-6) expression in  $c\text{-Kit}^+\text{AA4.1}^+$  cells. Sca-1 is traditionally used to isolate HSCs present in FL and BM (13, 14, 16). However,  $c\text{-Kit}^+\text{AA4.1}^+$  cells were negative for Sca-1 expression (Fig. 4A), suggesting that Sca-1 is not expressed in hematopoietic progenitors in the early stage of development.

**Localization and Characterization of  $c\text{-Kit}^+\text{AA4.1}^+$  Cells in Developing Embryos.** We next searched the *in vivo* counterpart of ES-cell-derived  $c\text{-Kit}^+\text{AA4.1}^+$  cells in E9.5 embryos. Flow cytometric analysis showed that the cell subset was present abundantly in the YS and in small numbers in the CH (including the AGM region) of the embryo proper in a cell fraction deprived of Ter119 $^+$  primitive erythrocytes (Fig. 5A). The quantification result showed that  $\approx 20$ -fold more  $c\text{-Kit}^+\text{AA4.1}^+$  cells existed in the YS compared with the CH of the embryos (Table 1), suggesting that the YS is a major site for producing the earliest lymphohematopoietic progenitors (7, 10). The  $c\text{-Kit}^+\text{AA4.1}^+$  cells were



**Fig. 5.** Characterization of  $c\text{-Kit}^+\text{AA4.1}^+$  cells present in embryonic day 9.5 (E9.5) mice. (A) Presence of  $c\text{-Kit}^+\text{AA4.1}^+$  cells in the yolk sac (YS) and caudal half (CH) of developing embryos. A GFP-Tg male was crossed with non-Tg female to obtain GFP $^+$  embryos to avoid the possible contamination of maternal CD45 $^+$  cells. (B) Cell surface marker expression of  $c\text{-Kit}^+\text{AA4.1}^+$  cells in the YS. (C) Hematopoietic colony-forming activity of  $c\text{-Kit}^+\text{AA4.1}^+$  cells present in the YS. Representative pictures of macrophage (M), erythroid (E), granulocyte-macrophage (GM), and mixed-type (mix) colonies are shown. (D and E) The potential of  $c\text{-Kit}^+\text{AA4.1}^+$  cells present in the YS and CH to differentiate into B (D) and T (E) lineage cells was examined using OP9 and OP9DL1 stromal cells, respectively. Representative results from 4 (YS) and 2 (CH) independent experiments each initiated with pooled littermate embryos are shown. The plots shown are pregated on FSC/SSC. The numbers indicate the percentages within the parent population.

detected in at least the YS at E8.5 (Fig. S6), although CD45 expression was not detected at that time. Consistent with ES-cell-derived c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells, the cell surface phenotype of c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells in the developing mice was CD34<sup>+</sup>CD41<sup>+</sup>Sca-1<sup>-</sup> (Fig. 5B), and the cells formed myeloid lineage colonies in methylcellulose (Fig. 5C). The c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells, isolated from either the YS or the CH of E9.5 embryos, gave rise to B lymphocytes (Fig. 5D) and  $\alpha\beta/\gamma\delta$ -lineage T lymphocytes when transferred onto OP9 and OP9-DL1 (61) stromal cell lines (Fig. 5E), respectively. The efficiency of these cells in generating lymphocytes was comparable to that of BM c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lin<sup>-</sup> cells. Thus, AA4.1 is a marker of the earliest lymphohematopoietic progenitor of developing embryos.

## Discussion

We showed that hematopoietic activity from the early differentiation of ES cells resides in c-Kit<sup>+</sup>Lin<sup>-</sup> cells. We found that the cell population is further separated into two distinct cell subsets based on AA4.1 expression. We demonstrated that the AA4.1<sup>+</sup> cell subset gives rise to both myeloid and lymphoid lineage cells, whereas the differentiation potential of the AA4.1<sup>-</sup> cell subset is largely restricted to myeloid cell lineages (Figs. 2 and 3C). Although performing clonal analysis is difficult until we improve the culture conditions so that AA4.1<sup>+</sup> cells survive at a high efficiency after the cell sorting, experiments must be done in the future to confirm that single cells have both myeloid and lymphoid potential. On the basis of the  $\beta$ -globin expression pattern (Fig. 3A), both AA4.1<sup>+</sup> and AA4.1<sup>-</sup> cell subsets should be classified as definitive-type hematopoietic progenitors. We showed that the c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells gave rise to some c-Kit<sup>+</sup>AA4.1<sup>-</sup> cells but not vice versa (Fig. S2). However, whether all of the c-Kit<sup>+</sup>AA4.1<sup>-</sup> cells originate from c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells is still unclear, because we detected some c-Kit<sup>+</sup>AA4.1<sup>-</sup> cells together with c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells at earlier time points. AA4.1 marks the majority of CD41<sup>+</sup> cells; however, 1/5 of the CD41<sup>+</sup> cells were AA4.1<sup>-</sup> (Fig. 3B). Because AA4.1<sup>-</sup> cells did not give rise to lymphoid cells (Fig. 3C), the cell fractionation method using AA4.1 antibody provides a way to isolate only the most immature hematopoietic cell subset from the ES cell culture. The phenotypic characterization of the first lymphohematopoietic cells in mouse ES cultures should allow the identification of their immediate precursors and which other mesodermal lineage cells can be derived from these precursors (30).

Despite the *in vitro* potency to generate both myeloid and lymphoid lineage cells, we could not detect *in vivo* engraftment of the c-Kit<sup>+</sup>Lin<sup>-</sup>AA4.1<sup>+</sup> cells (Fig. S3 and Fig. S4). The results indicate that even the earliest hematopoietic progenitors derived from ES cells are not competent to engraft mice. Our results also indicate that endogenous *HOXB4* expression (Fig. 4B) is not sufficient to provide ES cells with engraftment potency. The transplantation failure is not due to immunological surveillance through T, B, and NK cells nor to a cell survival problem (Fig. S3 and Fig. S4). At least, CXCR4, integrin  $\alpha 4$ , and integrin  $\beta 1$  were expressed on ES-cell-derived progenitors as homing molecules (Fig. S5). Our results are consistent with those of past studies that reported the inability of genetically unmodified ES-cell-derived progenitors to engraft mice (27). Contrary to our study, Potocnik et al. (62) reported that AA4.1<sup>+</sup>B220<sup>-</sup> cells derived from ES cells exhibit some potential for lymphoid engraftment in *Rag1*-deficient mice. One possible explanation for these contrasting observations is that the cell subset used by Potocnik et al. represents lymphoid-committed cells because these cells were isolated as late as day 15 of differentiation, a time point at which c-Kit<sup>+</sup>Lin<sup>-</sup>AA4.1<sup>+</sup> cells were no longer detected in our assay. The expression of cell surface molecules in c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells is consistent with that of embryonic stage HSCs except that the cells do not express Sca-1 antigen (Fig. 4

(14, 16, 43–46, 58, 60, 63). The *in vivo* counterpart of c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells was found mainly in the YS, with some cells in the CH of the embryo proper (Fig. 5 and Table 1), and the cells gave rise to both myeloid and lymphoid lineages in culture. Further studies are required to determine the exact location of c-Kit<sup>+</sup>AA4.1<sup>+</sup> cells within the YS and CH of developing mice (64). Yolk sac blood island cells taken from E8 and E9 donors fail to engraft adult irradiated syngeneic or congenic mice (3), yet the same cells transplanted *in utero* into the YS cavities of E8–E10 haploidentical hosts engraft and give rise to myeloerythroid day 10 spleen colonies and donor-derived T cells in the hosts at all ages tested (7). The cell tracking technique also revealed the contribution of early YS cells to adult hematopoiesis (11). We propose that our ES-cell-derived c-Kit<sup>+</sup>Lin<sup>-</sup>AA4.1<sup>+</sup> cells and the homologous cells in the YS and CH require signals *in vivo* to transit to fetal, transplantable HSCs. Sca-1 expression may be acquired during the switch.

In conclusion, we demonstrated that expression of AA4.1 marks the earliest lymphohematopoietic progenitors in ES cell culture and in early embryos. This is the clear demonstration that genetically unmodified ES cells give rise to multipotent hematopoietic progenitors with both myeloid and lymphoid lineage potentials *in vitro*. Our findings should provide helpful guidance for the therapeutic utilization of human pluripotent stem cells and will facilitate the understanding of how HSCs develop in embryos.

## Materials and Methods

**Cell Culture.** Mouse D3 ES cells (65), R1 ES cells (28), D3 ES cell lines expressing EGFP under the control of human EF-1 $\alpha$  promoter or CAG promoter (provided by Shin-ichi Hayashi, Tottori University, Japan), D3 ES cells overexpressing human Bcl-2 (22), OP9 stromal cells (36), OP9-DL1 (61), or ST2 stromal cells (34) were maintained as described earlier (24). To induce hematopoietic differentiation of ES cells *in vitro*, cells were placed on ST2 or OP9 stromal cells in MEM  $\alpha$  medium (Gibco) supplemented with 10% or 20% FBS (HyClone), respectively. On day 5 or day 6 of differentiation, colonies were dissociated with 0.25% trypsin and 0.5 mM EDTA (Gibco) and replated on freshly prepared stromal cell lines. For FACS and analysis, cells were collected by dissociating colonies with Hanks-based Cell Dissociation Buffer (Gibco) up to day 6 of differentiation and thereafter by pipetting. For B or T lymphocyte culture, cells were placed and cultured in RPMI medium 1640 supplemented with 5% FBS, 50  $\mu$ M 2-mercaptoethanol, and 10 ng/mL recombinant murine IL-7 on OP9 or cultured in MEM  $\alpha$  medium supplemented with 20% FBS on OP9-DL1, respectively.

**Antibodies.** The following monoclonal antibodies were used in this study: AA4.1, 6B2 (anti-B220), KT31.1 (CD3), GK1.5 (CD4), 53–6.7 (CD8), 6D5 (CD19), RAM34 (CD34), MWRReg30 (CD41), 30-F11 (CD45), 2B8 (c-Kit), 2B11/CXCR4 (CXCR4), 8C5 (Gr-1), II/41 (IgM), M1/70 (Mac-1), E13–161.7 (Sca-1), H57–597 (TCR $\beta$ ), Ter119, R1–2 ( $\alpha 4$  integrin), Ha2/5 ( $\beta 1$  integrin), GL3 ( $\gamma\delta$ TCR).

**Mice.** Mice were purchased from CLEA Japan and maintained in the Institute of Laboratory Animals at Mie University or bred and maintained in Stanford University's Research Animal Facility. All experiments were performed according to the guidelines of the animal committee of Mie University or Stanford Administrative Panel on Laboratory Animal Care.

**Cell Preparation from Embryos.** Caudal half and YS obtained from timed-mated C57BL/6J females were incubated with 1 mg/mL collagenase (Wako) in 2% FBS/HBSS for 30 min at 37 °C. A single-cell suspension prepared by pipetting after the incubation was used for the experiments.

**Colony-Formation Assay, FACS, and RT-PCR.** See *SI Materials and Methods*.

**ACKNOWLEDGMENTS.** We thank L. Jerabek and M. Yamada for laboratory management, C. Richter for antibody production, L. Hidalgo for animal care, J. C. Zúñiga-Pflücker for the OP9-DL1 cells, and S. I. Hayashi for the ES cell lines. This work was supported by National Institutes of Health Grants R01HL058770 and R01CA086065, by a gift from the Smith Family Foundation (to I.L.W.), and by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to T.Y.). T.Y. was partly supported by a fellowship from the Uehara Memorial Foundation. N.H. was supported by a fellowship from the Japan Society for the Promotion of Science.



- Morrison SJ, Uchida N, Weissman IL (1995) The biology of hematopoietic stem cells. *Annu Rev Cell Dev Biol* 11:35–71.
- Haar JL, Ackerman GA (1971) A phase and electron microscopic study of vasculogenesis and erythropoiesis in the yolk sac of the mouse. *Anat Rec* 170:199–223.
- Medvinsky AL, Samoylina NL, Müller AM, Dzierzak EA (1993) An early pre-liver intra-embryonic source of CFU-S in the developing mouse. *Nature* 364:64–67.
- Gekas C, Dieterlen-Lièvre F, Orkin SH, Mikkola HK (2005) The placenta is a niche for hematopoietic stem cells. *Dev Cell* 8:365–375.
- Ottersbach K, Dzierzak E (2005) The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. *Dev Cell* 8:377–387.
- Delassus S, Cumano A (1996) Circulation of hematopoietic progenitors in the mouse embryo. *Immunity* 4:97–106.
- Weissman IL, Papaioannou VE, Gardner RL (1978) Fetal hematopoietic origins of the adult hemolymphoid system. *Differentiation of Normal and Neoplastic Hematopoietic Cells*. eds Clarkson B, Marks PA, Till JE (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY), pp 33–47.
- Medvinsky A, Dzierzak E (1996) Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell* 86:897–906.
- Cumano A, Dieterlen-Lievre F, Godin I (1996) Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. *Cell* 86:907–916.
- Yoder MC, et al. (1997) Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. *Immunity* 7:335–344.
- Samokhvalov IM, Samokhvalov NI, Nishikawa S (2007) Cell tracing shows the contribution of the yolk sac to adult haematopoiesis. *Nature* 446:1056–1061.
- Till JE, McCulloch EA (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 14:213–222.
- Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. *Science* 241:58–62.
- Ikuta K, et al. (1990) A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. *Cell* 62:863–874.
- Morrison SJ, Weissman IL (1994) The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. *Immunity* 1:661–673.
- Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL (1995) The purification and characterization of fetal liver hematopoietic stem cells. *Proc Natl Acad Sci USA* 92:10302–10306.
- Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292:154–156.
- Martin GR (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci USA* 78:7634–7638.
- Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126:633–676.
- Williams RL, et al. (1988) Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. *Nature* 336:684–687.
- Smith AG, et al. (1988) Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. *Nature* 336:688–690.
- Yamane T, Dylla SJ, Muijtjens M, Weissman IL (2005) Enforced Bcl-2 expression overrides serum and feeder cell requirements for mouse embryonic stem cell self-renewal. *Proc Natl Acad Sci USA* 102:3312–3317.
- Nakano T, Kodama H, Honjo T (1994) Generation of lymphohematopoietic cells from embryonic stem cells in culture. *Science* 265:1098–1101.
- Yamane T, et al. (1997) Development of osteoclasts from embryonic stem cells through a pathway that is *c-fms* but not *c-kit* dependent. *Blood* 90:3516–3523.
- Wiles MV, Keller G (1991) Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. *Development* 111:259–267.
- Schmitt TM, et al. (2004) Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. *Nat Immunol* 5:410–417.
- Müller AM, Dzierzak EA (1993) ES cells have only a limited lymphopoietic potential after adoptive transfer into mouse recipients. *Development* 118:1343–1351.
- Forrester LM, Bernstein A, Rossant J, Nagy A (1991) Long-term reconstitution of the mouse hematopoietic system by embryonic stem cell-derived fetal liver. *Proc Natl Acad Sci USA* 88:7514–7517.
- Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC (1993) Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. *Proc Natl Acad Sci USA* 90:8424–8428.
- Ueno H, Weissman IL (2006) Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands. *Dev Cell* 11:519–533.
- Perlingeiro RC, Kyba M, Daley GQ (2001) Clonal analysis of differentiating embryonic stem cells reveals a hematopoietic progenitor with primitive erythroid and adult lymphoid-myeloid potential. *Development* 128:4597–4604.
- Kyba M, Perlingeiro RC, Daley GQ (2002) HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. *Cell* 109:29–37.
- Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ (2005) Embryonic stem cell-derived hematopoietic stem cells. *Proc Natl Acad Sci USA* 102:19081–19086.
- Ogawa M, et al. (1988) B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. *EMBO J* 7:1337–1343.
- Yoshida H, et al. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. *Nature* 345:442–444.
- Kodama H, Nose M, Niida S, Nishikawa S, Nishikawa S (1994) Involvement of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells. *Exp Hematol* 22:979–984.
- Ogawa M, et al. (1991) Expression and function of c-kit in hemopoietic progenitor cells. *J Exp Med* 174:63–71.
- Ikuta K, Weissman IL (1992) Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. *Proc Natl Acad Sci USA* 89:1502–1506.
- Keller G, Kennedy M, Papayannopoulou T, Wiles MV (1993) Hematopoietic commitment during embryonic stem cell differentiation in culture. *Mol Cell Biol* 13:473–486.
- Yamane T, Hayashi S, Mizoguchi M, Yamazaki H, Kunisada T (1999) Derivation of melanocytes from embryonic stem cells in culture. *Dev Dyn* 216:450–458.
- Ema H, Takano H, Sudo K, Nakauchi H (2000) In vitro self-renewal division of hematopoietic stem cells. *J Exp Med* 192:1281–1288.
- Domen J, Weissman IL (2000) Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. *J Exp Med* 192:1707–1718.
- Huang H, Auerbach R (1993) Identification and characterization of hematopoietic stem cells from the yolk sac of the early mouse embryo. *Proc Natl Acad Sci USA* 90:10110–10114.
- Jordan CT, McKearn JP, Lemischka IR (1990) Cellular and developmental properties of fetal hematopoietic stem cells. *Cell* 61:953–963.
- Jordan CT, et al. (1995) Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. *Exp Hematol* 23:1011–1015.
- Trevisan M, Iscove NN (1995) Phenotypic analysis of murine long-term hemopoietic reconstituting cells quantitated competitively in vivo and comparison with more advanced colony-forming progeny. *J Exp Med* 181:93–103.
- Lee G, Namen AE, Gillis S, Ellingsworth LR, Kincade PW (1989) Normal B cell precursors responsive to recombinant murine IL-7 and inhibition of IL-7 activity by transforming growth factor-beta. *J Immunol* 142:3875–3883.
- Vieira P, Cumano A (2004) Differentiation of B lymphocytes from hematopoietic stem cells. *Methods Mol Biol* 271:67–76.
- Goldman JP, et al. (1998) Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor  $\gamma$  chain. *Br J Haematol* 103:335–342.
- Domen J, Cheshier SH, Weissman IL (2000) The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. *J Exp Med* 191:253–264.
- Kawabata K, et al. (1999) A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. *Proc Natl Acad Sci USA* 96:5663–5667.
- Ma Q, Jones D, Springer TA (1999) The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. *Immunity* 10:463–471.
- Neuhaus H, et al. (1991) Cloning and expression of cDNAs for the  $\alpha$  subunit of the murine lymphocyte-Peyer's patch adhesion molecule. *J Cell Biol* 115:1149–1158.
- Miyake K, Weissman IL, Greenberger JS, Kincade PW (1991) Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. *J Exp Med* 173:599–607.
- Wagers AJ, Allsopp RC, Weissman IL (2002) Changes in integrin expression are associated with altered homing properties of Lin<sup>-lo</sup>Thy1.1<sup>lo</sup>Sca-1<sup>+</sup>c-kit<sup>+</sup> hematopoietic stem cells following mobilization by cyclophosphamide/granulocyte colony-stimulating factor. *Exp Hematol* 30:176–185.
- Potocnik AJ, Brakebusch C, Fässler R (2000) Fetal and adult hematopoietic stem cells require  $\beta 1$  integrin function for colonizing fetal liver, spleen, and bone marrow. *Immunity* 12:653–663.
- Elices MJ, Urry LA, Hemler ME (1991) Receptor functions for the integrin VLA-3: Fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. *J Cell Biol* 112:169–181.
- Mitjavila-Garcia MT, et al. (2002) Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. *Development* 129:2003–2013.
- Mikkola HK, Fujiwara Y, Schlaeger TM, Traver D, Orkin SH (2003) Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse embryo. *Blood* 101:508–516.
- Ferkowicz MJ, et al. (2003) CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo. *Development* 130:4393–4403.
- Schmitt TM, Zúñiga-Pflücker JC (2002) Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. *Immunity* 17:749–756.
- Potocnik AJ, Kohler H, Eichmann K (1997) Hemato-lymphoid in vivo reconstitution potential of subpopulations derived from in vitro differentiated embryonic stem cells. *Proc Natl Acad Sci USA* 94:10295–10300.
- Sánchez MJ, Holmes A, Miles C, Dzierzak E (1996) Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. *Immunity* 5:513–525.
- Petrenko O, et al. (1999) The molecular characterization of the fetal stem cell marker AA4. *Immunity* 10:691–700.
- Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R (1985) The in vitro development of blastocyst-derived embryonic stem cell lines: Formation of visceral yolk sac, blood islands and myocardium. *J Embryol Exp Morphol* 87:27–45.